CDK4 and lung carcinoma: Preclinical research showed that CDK4/6 inhibitors in combination with anti-PDL1 antibodies promote tumor regressions and the effect is accompanied by enhanced antigen presentation, T cell inflamed phenotype, and cytotoxic T cell-mediated clearance of lung cancer cells; moreover, this combination improves the overall survival rates in mouse tumor models (17, 40, 42).